Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Accera (Broomfield, CO) a biotechnology company developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells, closed a $35M Series C financing. Participants include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.